Responders, survivors on pazopanib characterized for advanced soft tissue sarcoma
Monday, February 10, 2014 - 17:01
in Health & Medicine
An analysis has confirmed the importance of known prognostic factors such as performance status and tumor grading for having a long-term outcome in patients treated with pazopanib for metastatic soft tissue sarcoma. Additionally, hemoglobin at baseline was found to be a new prognostic factor.